ClinicalTrials.gg
RecruitingNCT06088602CRISPPUpdated Jul 16, 2024

Cryoneurolysis for Acute Postoperative Pain Following Total Knee Arthroplasty

An interventional study of Cryoneurolysis and Sham in Acute Postoperative Pain, sponsored by Copenhagen University Hospital, Hvidovre. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Copenhagen University Hospital, Hvidovre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies in Pain, Postoperative with a site in Denmark — 8 open to participants now, 9 under way, 2 of them phase 3. Pain, Postoperative · Denmark.

Planned enrollment
97th of 129
44 · median 72
Started
2024
with 4 others
No phase
36 of 180
2 open now
Registered
172nd of 180
by date
Lead sponsor
5 of 180
Copenhagen University Hospital, Hvidovre

Among the 180 studies in Pain, Postoperative with a site in Denmark, this one is the 97th largest by planned enrollment of the 129 interventional ones that give a count, is one of 5 that started in 2024, is one of 36 with no phase, and was the 172nd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 180 studies in Pain, Postoperative with a site in Denmark are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Pain, Postoperative with a site in Denmark, or all of them as a file.
02

Study summary

Cryoneurolysis is a regional anaesthetic technique that works by freezing peripheral sensory nerves. This technique can potentially provide analgesia after total knee arthroplasty (TKA). However, the technique is expensive and comprehensive. Pain 24 hours after surgery is associated with high amounts of late acute pain. Therefore, the aim of the current study was to compare the effect of postoperative cryoanalgesia with a sham treatment on acute postoperative pain in TKA patients with moderate to severe pain on the first postoperative day. The cryoanalgesia treatment will be performed 24 hours after surgery. Afterward, the patients will be followed for 24 weeks to determine the level of pain among other outcomes.

Read the detailed description

Background Total knee arthroplasty (TKA) is a frequently performed procedure and is expected to increase in numbers due to the aging population and growing obesity rates. Fast-track regimes with multimodal opioid-sparing analgesia have improved postoperative outcomes. However, a subset of patients still experiences unsatisfactory levels of postoperative pain in the weeks following surgery, potentially delaying mobilization and recovery as well as increasing the need for opioid analgesics. Current recommendations for pain management following TKA according to the Procedure Specific Postoperative Pain Management (PROSPECT) Working Group include paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, local infiltration analgesia, and single shot adductor canal block (ACB). However, the role of ACBs for pain after TKA has been under extensive debate in recent years. While an ACB may provide some pain relief, the duration of pain control is usually less than 24 h and the effect on length of stay (LOS) and opioid consumption is questionable.

In the past decades, cryoneurolysis has been used to treat acute pain following herniorrhaphy, tonsillectomy, and thoracotomy via the surgical incision. The emergence of percutaneous cryoprobes and the use of ultra-sound guided techniques has allowed for an increase in potential applications. Recently, the use of cryoneurolysis has gained attention as a potential regional anesthetic technique for the treatment of knee pain. Cryoneurolysis works by freezing peripheral nerves with temperatures in the range of -20⁰C to -100⁰C, causing a Wallerian degeneration of nerve axons distal to the treatment site. This process involves loss of the relative continuity of the axon and its covering of myelin but with a preservation of the surrounding endo-, peri-, and epineurium, thus allowing normal axonal regeneration and remyelination. Axons regenerate at a rate of 1-2 mm/day. Thus, resulting in a nerve block that typically will resolve with full recovery within weeks to months depending on the site of treatment.

The effect of cryoneurolysis on knee pain has been documented in a few studies. A randomized, double-blind, sham-controlled trial found that cryoneurolysis reduced symptoms of knee osteoarthritis for up to 150 days. A retrospective chart-review of 100 patients undergoing TKA found that cryoneurolysis significantly lowered LOS, reduced opioid consumption until 12 weeks after surgery, and reduced pain at the 2- and 6-weeks follow-up. Another retrospective analysis in 267 patients undergoing TKA found a comparable reduction in opioid requirements, pain, and LOS in patients treated with cryoneurolysis compared with historic controls. A recent RCT comparing cryoneurolysis to standard of care in 124 patients undergoing TKA found that cryoneurolysis reduced opioid consumption at 72 h, 6 weeks and 12-week follow-ups.

Although these findings are promising, cryoneurolysis is expensive and comprehensive, and might not be relevant in all patients receiving multimodal analgesia with COX-2 inhibitors, paracetamol, local infiltration analgesia, and high-dose steroid in a fully implemented enhanced recovery program. Several risk factors have been associated with a high pain response including age, gender, preoperative pain, psychological profile, and quantitative sensory testing (QST). However, when including postoperative pain in the prediction of acute pain, movement-evoked pain 24 h postoperatively is the best predictor for pain the week following surgery.

Using postoperative pain 24 h after surgery as a predictor of a sustained high pain response, we hypothesized that postoperative cryoanalgesia compared to a local anesthesia (LA) block with sham cryo treatment would reduce pain in patients with moderate to severe pain following TKA 2-7 days after surgery.

Aim To compare the effect of postoperative cryoanalgesia with a sham treatment consisting of LA block only on postoperative pain in the first week after surgery in TKA patients with moderate to severe pain on the first postoperative day.

Study plan In the outpatient clinic, the screening procedure will be performed among patients planned for TKA by the surgeons. Patients will be asked by orthopedic staff whether they may be contacted regarding the research project. The research staff will then contact potential patients either in person or via telephone. The written study information will be explained - either at the outpatient clinic or via telephone by the investigator.

All patients receive both spoken and written information. Information is given in a separate closed room without interruptions. All patients are given the chance of an additional meeting with the chance of bringing a relative. All patients must give a signed informed consent on paper prior to inclusion to participate in the study. The patient will sign the consent form on day 1 after surgery.

Perioperative treatment The pre-, intra-, and postoperative treatment-course follows the local operating procedures and common clinical guidelines implemented at the Dept. of Orthopedic Surgery, Hvidovre Hospital.

Preoperative standard treatment Preoperatively, the patient is examined by a specialized arthroplasty surgeon, and a basic preoperative health examination is done, along with a specialized anesthesiologic assessment planning the anesthesia for the TKA operation.

On the morning of surgery the patient will be given:

Celebra 400 mg Paracetamol 1 g

Anesthesia All included patients will receive general anesthesia or a neuraxial blockade in the form of a spinal anesthesia administered at level L2-L4, by injecting 2-3 ml of hyperbaric bupivacaine 0.5%. If spinal anesthesia is performed, perioperative sedation with propofol or other sedatives is optional and done in agreement with the patient. According to local guidelines, dexamethasone 0.3 mg/kg or 1 mg/kg IV rounded up to nearest 10 mg will be administered prior to surgery to patients with a pain catastrophizing scale score ≤ 20 or > 20, respectively. A supplement of local infiltration analgesia is administered directly into the surrounding tissue of the knee at the end of surgery, according to local operating procedure.

Tranexamic acid is administered as 1 g preoperatively, 1 g 3 h postoperatively, and 1 g in the surgical ward according to local operating procedure to prevent bleeding.

Surgical procedure A medial parapatellar approach will be used. No tourniquet is used. Following insertion of the prosthesis, local infiltration analgesia (LIA) with 200 mL 0.2% Ropivacaine will be injected in the posterior capsule, periarticular tissues and subcutaneous tissue. Joint capsule, subcutis and skin are closed with standard 3-layer closure and a compression bandage is applied. No drains are used. All patient will be operated with cemented components and patella resurfacing.

Standard postoperative treatment

The postoperative multimodal analgesic regimen consists of:

Celebra 200 mg x 2, for 7 days. Paracetamol 1 g x 4, for 7 days. Morphine 10-20 mg or opioid equivalents administered only as rescue opioids.

Intervention The intervention will take place after the inclusion at 20-32 h after TKA surgery. The procedure will be performed at the Dept. of Anesthesiology.

Cryoneurolysis mechanism of action Cryoneurolysis will be performed on the superficial genicular nerves (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland). The cryoprobe works by passing carbon dioxide at a relatively high pressure down the shaft, through a small orifice and into a closed tip at a much lower pressure. According to the Joule-Thomson effect, this drop in pressure causes a dramatic decrease in temperature which leads to a rapid expansion and absorption of heat. Afterwards the gas moves back up through a larger diameter tube. Importantly, this closed loop allows no gas to escape into the surrounding tissue. The intense cold created (approximately -70⁰C) causes a Wallerian degeneration, thereby reversibly destroying the nerve axon with retention of the endo-, peri-, and epineurium. Since the architecture of the nerve remains intact, the nerve axon can grow out along its normal path which occurs with approximately 1-2 mm/day. The drop in temperature cannot be lower than the boiling point for the gas used, which for carbon dioxide is -79⁰C. Irreversible degeneration of nerve tissue occurs at about -100⁰C which allows for a wide safety margin.

Procedure technique

Cryo-group:

The patient is placed in a supine position with a sheet between the upper and lower part of the body, thus blinding the patient from the intervention allocation. The procedure is performed using a linear array ultrasound probe. Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator (Stimuplex HNS 12, B Braun, Melsungen, Germany) is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.

Sham-group:

The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.

Study specific assessments Pain is rated by the patient before the intervention, after the initial LA injection, at home on days 2-7 and at the 2-, 4-, 12-, and 24 weeks follow-up via telephone.

A Visual Analog Scale (VAS 0-100) is used. On days 1-7 patients mark their pain in the electronic CRF twice a day (Appendix 5). If the patient is not able to complete the ratings electronically, a physical pain diary will be provided. Pain is rated by the patient at rest, during a 5-meter walk test, and during sleep. At the hospital and at the follow-ups patients are asked to rate their pain at rest and during a 5-meter walk test.

Use of rescue-analgesics (opioids) or other specific pain-relieving actions that differ from standard treatment is noted in the CRF.

The presence of dysesthesia or other side effects will be evaluated at each follow-up.

Other clinical data collected

  • Demographical data (gender, age, height, weight, co-morbidity, American Society of Anesthesiologist (ASA) score)
  • Preoperative opioids/strong analgesics
  • Pain Catastrophizing Scale (PCS)
  • Surgical data (date of surgery, indication, surgical time, procedure information, intraoperative bleeding, transfusion data, perioperative analgesics)
  • Type and dosage of analgesics.
  • Deviations from standard treatment
  • Quality of sleep, lethargy, dizziness, and nausea, pre- and postoperative registration, on a NRS (0-10)
  • Adverse events throughout the hospitalization and at each follow-up
  • Neuropathic Pain Scale for Postsurgical Patients (NeuPPS)

Data protection The study will be conducted according to the General Data Protection Regulation and The Data Protection Act. All information will be treated confidentially, and all data will be pseudonymized with a code.

All research personnel are subject to professional secrecy. The investigators will keep an ID-list on all patients included in the study, containing full name, social security number and participant-ID.

A screening log is kept electronically in REDCap containing date of screening/surgery, age, reasons for not including in study on all patients screened for participation.

Collected data will be entered in the electronic CRF. This CRF and the EPJ will be made available for third parties in accordance with Danish Law. This means available for inspection by the Danish Medical Agency or other health authorities.

Patients will be informed that results will be stored and analyzed, and that anonymity will be respected. Data will always be stored in accordance with the regulations by DPA. Furthermore, participants will be informed of the possibility of inspection of the data from public authorities. Investigator ensures that the study follows the principles of Good Clinical Practice.

03

Conditions studied

  • Acute Postoperative Pain

Browse trials for

Keywords

  • Cryoanalgesia
  • Acute postoperative pain
  • Total knee arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Primary unilateral total knee arthroplasty
  • Ability to participate in the study (understand written and spoken Danish language, self-reported pain and satisfaction)
  • Signed written form
  • Pain (VAS 0-100 mm) ≥ 45 during a 5-meter walk test at 24 h (20-28h) postoperatively

Exclusion criteria

Exclusion Criteria:

  • Ongoing treatment of systemic or other treatment apart from inhaled steroids
  • Insulin-dependent diabetes
  • Pregnancy or breastfeeding
  • Mental disability that could impair a patient's decision-making capability of giving and not enabling valid data collection.
  • Patients with known diagnoses of schizophrenia, ongoing psychosis, bipolar disease and/or a history of ongoing anti-psychotic treatment.
  • Patients with modulated pain-reception (experience) based on other diseases or injuries, e.g. spinal cord or brain injury, severe polyneuropathies or neurologic disorders.
  • Posttraumatic osteoarthritis as reason for total knee arthroplasty
  • Bleeding disorder
  • Localized infection in the treatment area
  • Cryoglobulinemia, cold urticaria, paroxysmal cold haemoglobinuria, or Raynaud's syndrome
  • Perioperative peripheral nerve block
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Cryo-group

    Postoperative cryoneurolysis of the superficial genicular nerves, i.e., the infrapatellar branches of the saphenous nerve (ISN) and the anterior femoral cutaneous nerve (AFCN).

    Procedure: Cryoneurolysis

  • Sham comparator
    Sham-group

    Postoperative sham cryoneurolysis of the lower extremity.

    Procedure: Sham

Interventions

  • ProcedureCryoneurolysis

    Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.

  • ProcedureSham

    The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.

06

What researchers measure

Primary outcomes

  1. Cumulated pain during walking days 2-7

    Cumulated pain (VAS 0-100 mm) upon ambulation in a 5-meter walk test on days 2-7 postoperatively after surgery.

    Time frame: Days 2-7 after surgery

Secondary outcomes

  1. Pain at follow-ups

    Pain (VAS 0-100) during rest and during 5-meter walk test at the 2 weeks, 4 weeks, 12 weeks, and 24 weeks follow-up

    Time frame: 2-24 weeks after surgery

  2. Pain relief after block

    Pain relief immediately following blockade evaluated as ΔVAS 0-100 during a 5-meter walk test before and after the blockade

    Time frame: 24 hours after surgery

  3. Cumulated pain during rest and night days 2-7

    Cumulated pain at rest and during night from days 2-7

    Time frame: Days 2-7 after surgery

  4. Quality of sleep

    Quality of sleep assessed by the patient on a scale of 0-10 from postoperative days 2-7

    Time frame: Days 2-7 after surgery

  5. Dizziness

    Dizziness assessed by the patient on a scale of 0-10 from postoperative days 2-7

    Time frame: Days 2-7 after surgery

  6. Fatigue

    Fatigue assessed by the patient on a scale of 0-10 from postoperative days 2-7

    Time frame: Days 2-7 after surgery

  7. Nausea

    Nausea assessed by the patient on a scale of 0-10 from postoperative days 2-7

    Time frame: Days 2-7 after surgery

  8. Use of rescue analgesics

    Cumulative use of rescue-analgesics from days 2-7, and at 2 weeks, 4 weeks, 12 weeks, and 24 weeks follow-up

    Time frame: 2 days to 24 weeks efter surgery

  9. Oxford knee score

    Oxford knee score at 12 weeks

    Time frame: 12 weeks after surgery

  10. Length of stay in hospital

    Length of stay in hospital, and reasons for prolonged stay (\>1 postoperative day) registered as "Why still in hospital"

    Time frame: Up to 24 weeks

  11. Reasons for re-admissions

    Reasons for re-admissions within 12 weeks

    Time frame: 12 weeks

  12. Morbidity

    Morbidity assessed as new illnesses or complications (4-, 12-, and 24 weeks follow-up by Electronic Patient Journal (EPJ) or telephone)

    Time frame: 24 weeks after surgery

  13. Mortality

    Mortality (4-, 12-, and 24 weeks follow-up by Electronic Patient Journal (EPJ) or telephone)

    Time frame: 24 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Husted H, Lunn TH, Troelsen A, Gaarn-Larsen L, Kristensen BB, Kehlet H. Why still in hospital after fast-track hip and knee arthroplasty? Acta Orthop. 2011 Dec;82(6):679-84. doi: 10.3109/17453674.2011.636682. Epub 2011 Nov 9. PubMed 22066560 ↗
  • Khan RS, Ahmed K, Blakeway E, Skapinakis P, Nihoyannopoulos L, Macleod K, Sevdalis N, Ashrafian H, Platt M, Darzi A, Athanasiou T. Catastrophizing: a predictive factor for postoperative pain. Am J Surg. 2011 Jan;201(1):122-31. doi: 10.1016/j.amjsurg.2010.02.007. Epub 2010 Sep 15. PubMed 20832052 ↗
  • Andersen LO, Gaarn-Larsen L, Kristensen BB, Husted H, Otte KS, Kehlet H. Subacute pain and function after fast-track hip and knee arthroplasty. Anaesthesia. 2009 May;64(5):508-13. doi: 10.1111/j.1365-2044.2008.05831.x. PubMed 19413820 ↗
  • Kehlet H, Joshi GP. The systematic review/meta-analysis epidemic: a tale of glucocorticoid therapy in total knee arthroplasty. Anaesthesia. 2020 Jul;75(7):856-860. doi: 10.1111/anae.14946. Epub 2019 Dec 4. No abstract available. PubMed 31802486 ↗
  • Callesen T, Bech K, Thorup J, Andersen J, Nielsen R, Roikjaer O, Kehlet H. Cryoanalgesia: effect on postherniorrhaphy pain. Anesth Analg. 1998 Oct;87(4):896-9. doi: 10.1097/00000539-199810000-00028. PubMed 9768790 ↗
  • Ip HY, Abrishami A, Peng PW, Wong J, Chung F. Predictors of postoperative pain and analgesic consumption: a qualitative systematic review. Anesthesiology. 2009 Sep;111(3):657-77. doi: 10.1097/ALN.0b013e3181aae87a. PubMed 19672167 ↗
  • Werner MU, Mjobo HN, Nielsen PR, Rudin A. Prediction of postoperative pain: a systematic review of predictive experimental pain studies. Anesthesiology. 2010 Jun;112(6):1494-502. doi: 10.1097/ALN.0b013e3181dcd5a0. PubMed 20460988 ↗
  • Barnard D. The effects of extreme cold on sensory nerves. Ann R Coll Surg Engl. 1980 May;62(3):180-7. PubMed 7396346 ↗
  • Mustola ST, Lempinen J, Saimanen E, Vilkko P. Efficacy of thoracic epidural analgesia with or without intercostal nerve cryoanalgesia for postthoracotomy pain. Ann Thorac Surg. 2011 Mar;91(3):869-73. doi: 10.1016/j.athoracsur.2010.11.014. PubMed 21353017 ↗
  • Urban JA, Dolesh K, Martin E. A Multimodal Pain Management Protocol Including Preoperative Cryoneurolysis for Total Knee Arthroplasty to Reduce Pain, Opioid Consumption, and Length of Stay. Arthroplast Today. 2021 Jul 12;10:87-92. doi: 10.1016/j.artd.2021.06.008. eCollection 2021 Aug. PubMed 34286056 ↗
  • Ilfeld BM, Gabriel RA, Trescot AM. Ultrasound-guided percutaneous cryoneurolysis for treatment of acute pain: could cryoanalgesia replace continuous peripheral nerve blocks? Br J Anaesth. 2017 Oct 1;119(4):703-706. doi: 10.1093/bja/aex142. No abstract available. PubMed 29121277 ↗
  • Joshi GP, Stewart J, Kehlet H. Critical appraisal of randomised trials assessing regional analgesic interventions for knee arthroplasty: implications for postoperative pain guidelines development. Br J Anaesth. 2022 Aug;129(2):142-144. doi: 10.1016/j.bja.2022.04.019. Epub 2022 May 24. PubMed 35618537 ↗
  • Lunn TH, Andersen LO, Kristensen BB, Husted H, Gaarn-Larsen L, Bandholm T, Ladelund S, Kehlet H. Effect of high-dose preoperative methylprednisolone on recovery after total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. Br J Anaesth. 2013 Jan;110(1):66-73. doi: 10.1093/bja/aes345. Epub 2012 Sep 17. PubMed 22986420 ↗
  • Andersen KG, Christensen KB, Kehlet H, Bidstup PE. The Effect of Pain on Physical Functioning After Breast Cancer Treatment: Development and Validation of an Assessment Tool. Clin J Pain. 2015 Sep;31(9):794-802. doi: 10.1097/AJP.0000000000000156. PubMed 25679946 ↗
  • Riddle DL, Wade JB, Jiranek WA, Kong X. Preoperative pain catastrophizing predicts pain outcome after knee arthroplasty. Clin Orthop Relat Res. 2010 Mar;468(3):798-806. doi: 10.1007/s11999-009-0963-y. Epub 2009 Jul 8. PubMed 19585177 ↗
  • Rupp M, Lau E, Kurtz SM, Alt V. Projections of Primary TKA and THA in Germany From 2016 Through 2040. Clin Orthop Relat Res. 2020 Jul;478(7):1622-1633. doi: 10.1097/CORR.0000000000001214. PubMed 32168057 ↗
  • Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, Hubner M, Kassouf W, Muller S, Baldini G, Carli F, Naesheimh T, Ytrebo L, Revhaug A, Lassen K, Knutsen T, Aarsether E, Wiklund P, Patel HR. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS((R))) society recommendations. Clin Nutr. 2013 Dec;32(6):879-87. doi: 10.1016/j.clnu.2013.09.014. Epub 2013 Oct 17. PubMed 24189391 ↗
  • Lavand'homme PM, Kehlet H, Rawal N, Joshi GP; PROSPECT Working Group of the European Society of Regional Anaesthesia and Pain Therapy (ESRA). Pain management after total knee arthroplasty: PROcedure SPEcific Postoperative Pain ManagemenT recommendations. Eur J Anaesthesiol. 2022 Sep 1;39(9):743-757. doi: 10.1097/EJA.0000000000001691. Epub 2022 Jul 20. PubMed 35852550 ↗
  • Ju H, Feng Y, Yang BX, Wang J. Comparison of epidural analgesia and intercostal nerve cryoanalgesia for post-thoracotomy pain control. Eur J Pain. 2008 Apr;12(3):378-84. doi: 10.1016/j.ejpain.2007.07.011. Epub 2007 Sep 17. PubMed 17870625 ↗
  • Ilfeld BM, Preciado J, Trescot AM. Novel cryoneurolysis device for the treatment of sensory and motor peripheral nerves. Expert Rev Med Devices. 2016 Aug;13(8):713-25. doi: 10.1080/17434440.2016.1204229. Epub 2016 Jul 13. PubMed 27333989 ↗
  • Pabinger C, Lothaller H, Portner N, Geissler A. Projections of hip arthroplasty in OECD countries up to 2050. Hip Int. 2018 Sep;28(5):498-506. doi: 10.1177/1120700018757940. Epub 2018 May 21. PubMed 29783896 ↗
  • Romanini E, Decarolis F, Luzi I, Zanoli G, Venosa M, Laricchiuta P, Carrani E, Torre M. Total knee arthroplasty in Italy: reflections from the last fifteen years and projections for the next thirty. Int Orthop. 2019 Jan;43(1):133-138. doi: 10.1007/s00264-018-4165-7. Epub 2018 Oct 6. PubMed 30293141 ↗
  • Khanbhai M, Yap KH, Mohamed S, Dunning J. Is cryoanalgesia effective for post-thoracotomy pain? Interact Cardiovasc Thorac Surg. 2014 Feb;18(2):202-9. doi: 10.1093/icvts/ivt468. Epub 2013 Nov 11. PubMed 24218494 ↗
  • Mihalko WM, Kerkhof AL, Ford MC, Crockarell JR Jr, Harkess JW, Guyton JL. Cryoneurolysis before Total Knee Arthroplasty in Patients With Severe Osteoarthritis for Reduction of Postoperative Pain and Opioid Use in a Single-Center Randomized Controlled Trial. J Arthroplasty. 2021 May;36(5):1590-1598. doi: 10.1016/j.arth.2020.11.013. Epub 2020 Nov 14. PubMed 33279353 ↗
  • Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460. doi: 10.2106/JBJS.17.01617. PubMed 30180053 ↗
  • Dasa V, Lensing G, Parsons M, Harris J, Volaufova J, Bliss R. Percutaneous freezing of sensory nerves prior to total knee arthroplasty. Knee. 2016 Jun;23(3):523-8. doi: 10.1016/j.knee.2016.01.011. Epub 2016 Feb 10. PubMed 26875052 ↗
  • Robinson SR, Purdie GL. Reducing post-tonsillectomy pain with cryoanalgesia: a randomized controlled trial. Laryngoscope. 2000 Jul;110(7):1128-31. doi: 10.1097/00005537-200007000-00011. PubMed 10892682 ↗
  • Erivan R, Villatte G, Dartus J, Reina N, Descamps S, Boisgard S. Progression and projection for hip surgery in France, 2008-2070: Epidemiologic study with trend and projection analysis. Orthop Traumatol Surg Res. 2019 Nov;105(7):1227-1235. doi: 10.1016/j.otsr.2019.07.021. Epub 2019 Oct 9. PubMed 31606338 ↗
  • Chan EY, Blyth FM, Nairn L, Fransen M. Acute postoperative pain following hospital discharge after total knee arthroplasty. Osteoarthritis Cartilage. 2013 Sep;21(9):1257-63. doi: 10.1016/j.joca.2013.06.011. PubMed 23973139 ↗
  • Radnovich R, Scott D, Patel AT, Olson R, Dasa V, Segal N, Lane NE, Shrock K, Naranjo J, Darr K, Surowitz R, Choo J, Valadie A, Harrell R, Wei N, Metyas S. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. Osteoarthritis Cartilage. 2017 Aug;25(8):1247-1256. doi: 10.1016/j.joca.2017.03.006. Epub 2017 Mar 20. PubMed 28336454 ↗
  • Paredes AC, Pinto JM, Almeida A, Pinto PR. Predictive value of quantitative sensory testing for acute and chronic postsurgical pain after total joint arthroplasty: a systematic review. Pain. 2022 Mar 1;163(3):e385-e400. doi: 10.1097/j.pain.0000000000002385. PubMed 34224493 ↗
  • Mejdahl MK, Christoffersens KB, Andersen KG. Development and Validation of a Screening Tool for Surgery-Specific Neuropathic Pain: Neuropathic Pain Scale for Postsurgical Patients. Pain Physician. 2019 Mar;22(2):E81-E90. Erratum In: Pain Physician. 2019 May;22(3):305. PubMed 30921980 ↗
  • Trescot AM. Cryoanalgesia in interventional pain management. Pain Physician. 2003 Jul;6(3):345-60. PubMed 16880882 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized data from all participants will be made available upon request after the study is published.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will become available after the study is successfully published. There is no end date to the availability of the data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2025, 15 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 15 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 18, 2023
StartActual
Mar 19, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Oct 2025
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06088602
Lead sponsor
Copenhagen University Hospital, Hvidovre
Responsible party
Anders Deichmann Springborg (Dr., Copenhagen University Hospital, Hvidovre) — Principal investigator
First posted
Oct 18, 2023
Start date
Mar 19, 2024
Primary completion
Jun 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jul 16, 2024

Study contacts

Anders H Springborg, MD
Contact
andersspringborg@gmail.com
26815919
Nicolai B Foss, dr.med.
Contact
nicolai.bang.foss@regionh.dk
38625328
Anders H Springborg, MD
principal investigator · Copenhagen University Hospital, Hvidovre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion